Back to Search
Start Over
Oncolytics Biotech(R) Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer.
- Source :
- Immunotherapy Weekly; 5/21/2024, p687-687, 1p
- Publication Year :
- 2024
-
Abstract
- Oncolytics Biotech has received regulatory clearance to begin a new study on pancreatic cancer. The study will evaluate the use of pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) and an anti-PD-L1 inhibitor in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). The study is supported by a Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN). The results from this study could potentially improve outcomes for patients with pancreatic cancer. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 10908625
- Database :
- Supplemental Index
- Journal :
- Immunotherapy Weekly
- Publication Type :
- Periodical
- Accession number :
- 177284958